The negative modulation of TNF-α, IFN-γ, IL-10, IL-12p40, IL-17, may be associated with the reactivation of the infection observed in patients taking Infliximab or other TNF-α blockers, which increases the importance of screening for latent tuberculosis in patients with chronic inflammatory diseases candidates for the use of immunobiological TNF blockers. The gene discussed is IL17A; the disease is infection.